Bone Biologics Co. (NASDAQ:BBLG) Sees Large Increase in Short Interest

Bone Biologics Co. (NASDAQ:BBLG) was the recipient of a large increase in short interest in January. As of January 31st, there was short interest totalling 155,000 shares, an increase of 105.0% from the January 15th total of 75,600 shares. Based on an average daily volume of 185,000 shares, the days-to-cover ratio is currently 0.8 days. Currently, 29.1% of the company’s shares are sold short.

Bone Biologics Trading Down 1.9 %

NASDAQ BBLG traded down $0.02 during mid-day trading on Thursday, hitting $1.05. The company’s stock had a trading volume of 12,360 shares, compared to its average volume of 222,576. Bone Biologics has a 52-week low of $0.80 and a 52-week high of $4.49. The stock’s fifty day simple moving average is $1.06 and its two-hundred day simple moving average is $1.40.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.